Rody G. Sy

ORCID: 0000-0002-9637-3973
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lipoproteins and Cardiovascular Health
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Blood Pressure and Hypertension Studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Cardiovascular Health and Risk Factors
  • Cancer, Lipids, and Metabolism
  • Nutritional Studies and Diet
  • Obesity, Physical Activity, Diet
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Birth, Development, and Health
  • Global Public Health Policies and Epidemiology
  • Health Promotion and Cardiovascular Prevention
  • Child Nutrition and Water Access
  • Sodium Intake and Health
  • Chronic Disease Management Strategies
  • Diabetes Management and Education
  • Cardiovascular Function and Risk Factors
  • Lipid metabolism and disorders
  • Heart Rate Variability and Autonomic Control
  • Diabetes Management and Research
  • ECG Monitoring and Analysis
  • Adipokines, Inflammation, and Metabolic Diseases
  • Diabetes Treatment and Management
  • Protease and Inhibitor Mechanisms
  • Primary Care and Health Outcomes

Cebu Doctors' University
2025

Philippine General Hospital
2013-2024

University of the Philippines Manila
2004-2023

University of the Philippines System
2008-2021

National University Health System
2019

National University of Singapore
2019

Cardiovascular Institute of the South
2017

European Atherosclerosis Society
2016

Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels this enzyme are associated with an increased risk coronary events. Darapladib is a selective oral inhibitor A2.In double-blind trial, we randomly assigned 15,828 patients stable heart disease to receive either once-daily darapladib (at dose 160 mg) or placebo. The primary end point was composite cardiovascular death, myocardial infarction,...

10.1056/nejmoa1315878 article EN New England Journal of Medicine 2014-03-30
Katherine Wilemon Jasmine Patel Carlos A. Aguilar‐Salinas Catherine D. Ahmed Mutaz Al-Khnifsawi and 84 more Wael Almahmeed Rodrigo Alonso Khalid Al‐Rasadi Lina Badimón Luz Mery Bernal Martin P. Bogsrud Lynne T. Braun Liam R. Brunham Alberico L. Catapano Kristýna Cillíková Pablo Corral Regina Cuevas Joep C. Defesche Olivier Descamps Sarah D. de Ferranti Jean-Luc Eiselé Gerardo Elikir Emanuela Folco Tomáš Freiberger Francesco Fuggetta Isabel Gaspar Ákos G. Gesztes Urh Grošelj Ian Hamilton‐Craig Gabriele Hanauer-Mader Mariko Harada‐Shiba G. E. Hastings G. Kees Hovingh Maria Cristina de Oliveira Izar Allison Jamison Gunnar N. Karlsson Meral Kayıkçıoğlu Sue Koob Masahiro Koseki Stacey Lane Marcos M. Lima-Martínez Greizy López Tânia Leme da Rocha Martinez David Marais Letrillart Marion Pedro Mata Inese Maurina Diana Maxwell Roopa Mehta George A. Mensah André R. Miserez Dermot Neely Stephen J. Nicholls Atsushi Nohara Børge G. Nordestgaard Leiv Ose Athanasios Pallidis Jing Pang Jules Payne Amy L. Peterson Monica P. Popescu Raman Puri Kausik K. Ray Ashraf Reda Tiziana Sampietro Raúl D. Santos Inge Schalkers Laura Schreier Michael D. Shapiro Eric J.G. Sijbrands Daniel Soffer Claudia Stefanutti Mario Stoll Rody G. Sy Marta Lucía Tamayo Myra Tilney Lâle Tokgözoğlu Brian Tomlinson Antonio J. Vallejo‐Vaz Alejandra Vázquez-Cárdenas Patrícia Vieira de Luca David S Wald Gerald F. Watts Nanette K. Wenger M. Allison Wolf David A. Wood Aram Zegerius Thomas A. Gaziano Samuel S. Gidding

<h3>Importance</h3> Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity mortality due atherosclerotic cardiovascular disease. affects 1 in 200 250 people around the world of every race ethnicity. The lack general awareness FH among public medical community has resulted only 10% population being diagnosed adequately treated. World Health Organization recognized as a health priority 1998 during consultation meeting Geneva,...

10.1001/jamacardio.2019.5173 article EN JAMA Cardiology 2020-01-02

Abstract Aims Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients. Methods and results This prespecified analysis from ODYSSEY OUTCOMES compared effect alirocumab vs. placebo in 18 924 patients with recent acute coronary syndrome (ACS) according to age. We examined assigned treatment on occurrence primary study outcome, a composite heart disease death, myocardial infarction, ischaemic stroke,...

10.1093/eurheartj/ehz809 article EN cc-by-nc European Heart Journal 2019-10-29

Background We evaluated lipoprotein‐associated phospholipase A 2 (Lp‐ PLA ) activity in patients with stable coronary heart disease before and during treatment darapladib, a selective Lp‐ inhibitor, relation to outcomes the effects of darapladib STABILITY trial. Methods Results Plasma was determined at baseline (n=14 500); 1 month (n=13 709); serially (n=100) 3, 6, 18 months; end treatment. Adjusted Cox regression models associations between levels outcomes. At baseline, median level 172.4...

10.1161/jaha.116.003407 article EN cc-by-nc-nd Journal of the American Heart Association 2016-06-13

Background: We conducted a survey in 2008 to measure the prevalence of lifestyle-related diseases and risk factors Philippine adults.Methods: Stratified multistage sampling was used cover entire population adults aged 20 years or older. Using health questionnaires, anthropometric measurements, blood examinations, prevalences atherosclerosis-related were determined. Survey results compared with those obtained 2003.Results: Out 7700 eligible subjects, 64% 93.7% responded different items....

10.2188/jea.je20110095 article EN cc-by Journal of Epidemiology 2012-01-01

The objectives of this study were to determine the prevalence metabolic syndrome (MS) and its component risk factors among Filipinos using three sets criteria evaluate association between MS atherosclerotic cardiovascular disease diabetes mellitus. utilised a multi-staged cluster sampling design. was found be 11.9% by National Cholesterol Education Program/Adult Treatment Panel (NCEP/ATP III) criteria, 14.5% International Diabetes Federation (IDF) 18.6% NCEP/ATP III modified American Heart...

10.3132/dvdr.2008.007 article EN Diabetes and Vascular Disease Research 2008-01-01

Background: Metabolic syndrome(MetS) is an aggregation of multiple metabolic risk factors shown to lead the development cardiovascular disease. The International Diabetes Federation(IDF) and modified National Cholesterol Education Program Adult Treatment Panel Ⅲ(mNCEP) criteria are used in identifying MetS. This report will determine prevalence MetS its component Philippine cohort LIFE course study CARdiovascular disease Epidemiology(LIFECARE). Methods: Our recruited 3,072 participants aged...

10.5551/jat.21_sup.1-s9 article EN Journal of Atherosclerosis and Thrombosis 2014-01-01

10.1164/ajrccm.2025.211.abstracts.a5972 article EN American Journal of Respiratory and Critical Care Medicine 2025-05-01

Objective To evaluate the validity and reliability of Philippines (Tagalog) Short Form 36 Health Survey version 2 (SF-36v2®) standard questionnaire among Filipinos residing in two cities. Study Design Setting The official SF-36v2 (4-week recall) was pretested on 30 participants followed by formal informal cognitive debriefing. obtain feedback translation bilingual respondents, each question stated first English Tagalog. No revisions to original were needed except that thought it appropriate...

10.1371/journal.pone.0083794 article EN cc-by PLoS ONE 2013-12-26

Background: Familial Hypercholesterolemia (FH) is an autosomal dominant disease resulting from mutations of the LDL (LDLR) receptor gene leading to a diminished catabolism and elevated level cholesterol (LDL-C). It associated with increased risk for cardiovascular (CVD). The MEDPED (Make Early Diagnosis-Prevent Death) program, initiative cited by WHO Human Genetics Programme in their report on FH, initiated international collaboration identify follow-up patients FH globally. From...

10.5551/jat.12.276 article EN cc-by-nc-sa Journal of Atherosclerosis and Thrombosis 2005-01-01

Objective. This study aimed to estimate the prevalence of cardiovascular risk factors and metabolic syndrome among community health workers (CHWs) in selected villages Philippines. It also determined association urbanization socio-demographic characteristics with hypertension, diabetes mellitus CHWs.Methodology. A cross-sectional was conducted CHWs who were actively rendering service from communities at time study. Standardized interviews clinical measurements collected.Results. Of total 457...

10.15605/jafes.034.02.08 article EN cc-by-nc Journal of the ASEAN Federation of Endocrine Societies 2019-11-10

HDL-C has emerged as an important independent predictor of cardiovascular disease. The FNRI-HDL and NNHes Study Group in the Philippines reported that there was a high prevalence low HDL among Filipinos. Most cases are associated with secondary causes like Metabolic Syndrome. A primary cause reduced such increase Cholesteryl Ester Transfer Protein activity been identified.1. To determine phenotype frequency (TaqIB) polymorphism Filipinos risk factors. 2. association TaqIB levels...

10.5551/jat.14.116 article EN cc-by-nc-sa Journal of Atherosclerosis and Thrombosis 2007-01-01

Background: Virgin coconut oil (VCO) is promoted as a dietary supplement for people with various ailments. However, there have been few formal scientific studies to validate its health benefits. Objective: To determine the effect of VCO on lipid profile, FBS, weight and body mass index (BMI) healthy humans evaluate safety profile by determining creatinine, potassium, AST, ALT CBC Methods: Weight height were obtained from 30 males BMI was computed first visit. Baseline laboratories taken:...

10.3860/pjim.v48i2.2632 article EN Philippine Journal of Internal Medicine 2012-08-15
Coming Soon ...